Bli medlem
Bli medlem

Du är här


Saniona AB: Saniona postpones list change to Nasdaq Stockholm


October 18, 2016

Saniona, a leading biotech company in the field of ion channels, today
announces that the company has decided to postpone the planned change of
listing from Nasdaq First North Premier to Nasdaq Stockholm. The listing
process will restart in the spring of 2017.

As previously communicated, Saniona has initiated a process to transfer its
listing from Nasdaq First North Premier to Nasdaq Stockholm Small Cap during
2016. Saniona has planned the listing on Nasdaq Stockholm Small Cap under the
assumption that management fulfilled applicable competence and experience

One of the listing requirements applicable to companies to be listed at Nasdaq
Stockholm is that the management of the company should have sufficient
competence and experience to manage a company listed on a regulated market.

In order to fulfil the relevant listing requirement, the CEO, CFO or
equivalent senior executive member of the management team with responsibility
for disclosing information to the market should typically have at least
twelve months' experience within the last five years from a similar position
in a company listed on a regulated market, including Nasdaq First North
Premier, or comparable experience.

Nasdaq Stockholm's listing committee has, in a so called advanced ruling, come
to the conclusion that, based on an overall assessment, Saniona's management
team's experience will not fulfil the applicable listing requirement during

Experience from a company listed on Nasdaq First North Premier during 12
months will count to satisfy the relevant listing requirement. Saniona has
been listed on Nasdaq First North Premier since May 19, 2016. Therefore,
based on the existing management experience Saniona may be listed at Nasdaq
Stockholm Small Cap at the earliest during the second quarter of 2017.

For more information, please contact

Thomas Feldthus, EVP and CFO, Saniona, Mobile: +45 2210 9957,

This information is information that Saniona (publ) is obliged to make public
pursuant to the EU Market Abuse Regulation. The information was submitted for
publication, through the agency of the contact person set out above, at 18:30
CET on October 18, 2016.

About Saniona
Saniona is a research and development company focused on drugs for diseases of
the central nervous system, autoimmune diseases, metabolic diseases and
treatment of pain. The company has a significant portfolio of potential drug
candidates at pre-clinical and clinical stage. The research is focused on ion
channels, which makes up a unique protein class that enables and controls the
passage of charged ions across cell membranes. Saniona has ongoing
collaboration agreements with Boehringer Ingelheim GmbH, Upsher-Smith
Laboratories, Inc., Productos Medix, S.A de S.V and Saniona's Boston based
spinout Ataxion Inc., which is financed by Atlas Venture Inc. and Biogen Inc.
Saniona is based in Copenhagen, Denmark, where it has a research center of
high international standard. Saniona is listed at Nasdaq First North Premier
and has about 4,400 shareholders. Pareto Securities is Certified Advisor for
Saniona. The company's share is traded under the ticker SANION. Read more at

20161018 - PR - Saniona postpones Nasdaq transfer - UK


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Saniona AB via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.